The failure to reduce the infarct volume was possibly attributed to the timing, because the time taken in MSC-EV delivery is usually longer than the 3–6 h window required for tissue plasminogen activator (t-PA) therapy, the only stroke treatment. This evidence concerns the gene PLAT and stroke disorder.